Pharmacoepidemiology and Drug Safety · 2009 · 12 citations · 31 references
PharmacyPharmacologyToxicologyDevelopmental ToxicologyPerinatal EpidemiologyReproductive ToxicologyDevelopmental ToxicityPerinatal ToxicologyPregnancy PharmacologyPrenatal ToxicityPrenatal ToxicologyRisk Assessment For Developmental ToxicantsAdverse Drug ExposureConfidence Intervals For Odds RatiosDrug-induced TeratogenicityMaternal ToxicologyMaternal-fetal ToxicityPerinatal Drug ToxicityTeratogenic Exposure AssessmentToxicological Evaluation
OBJECTIVE: To study the effect of large doses of phenobarbital used for a suicide attempt during pregnancy for fetuses to estimate the teratogenic potential of phenobarbital. DESIGN AND SETTING: Comparative analysis of exposed children and their unexposed sibs born to pregnant patients who attempted suicide during pregnancy and admitted to the toxicological inpatient clinic, Budapest, 1960-1993. STUDY PARTICIPANTS: Of 1044 self-poisoned pregnant women, 88 used phenobarbital for suicide attempt and delivered newborn babies. MAIN OUTCOME MEASURES: Structural birth detects, i.e., congenital abnormalities (CAs). RESULTS: Doses ranged between 400 and 3000 mg of phenobarbital in 88 pregnant women who attempted suicide with this drug during pregnancy and later delivered live-born babies. Twelve (13.6%) of 88 exposed children and eight (10.3%) of 78 sibs were affected with CAs (odds ratios (OR) with 95%CI: 1.4, 0.6-3.5). Of 88 exposed children, 34 were born to mothers who attempted suicide with phenobarbital between the 3rd and 12th postconceptional weeks, the critical period of most CAs; 3 had CAs (diaphragmatic defect, multiple CA, undescended testis), but only diaphragmatic defect might be associated with phenobarbital used for suicide attempt. CONCLUSIONS: The use of phenobarbital once but extremely large doses in non-epileptic pregnant women does not seem to pose a significant risk for CAs. Our experiences show the feasibility and benefits of the disaster epidemiological self-poisoning model for estimating human teratogenic risks of drug exposure.
31
Birth Defects and Drugs in Pregnancy
John F. Tourville · American Journal of Health-System Pharmacy · 1977 · 858 citations
Medicine, Obstetrics, Pharmacology +13
The Teratogenicity of Anticonvulsant Drugs
Lewis B. Holmes, Elizabeth A. Harvey, Brent A. Coull et al. · New England Journal of Medicine · 2001 · 659 citations · Full text
Medicine, Obstetrics, Pediatrics +17
Annals of Internal Medicine · 1989 · 494 citations
ANTICONVULSANTS AND PARENTAL EPILEPSY IN THE DEVELOPMENT OF BIRTH DEFECTS
StuartC. Hartz, Victor Siskind, Allen A. Mitchell et al. · The Lancet · 1976 · 265 citations